Introduction {#Sec1}
============

Hepatocellular carcinoma (HCC), one of the most widespread and lethal cancers, is ranked as the fifth most common cancer and the third leading cause of cancer-related death. Approximately one million new HCC cases and almost an equal number of deaths are reported annually^[@CR1]^. HCC is a frequent malignancy in East and Southeast Asia and Sub-Saharan Africa, and it is particularly common in China, which accounts for nearly half of all cases^[@CR2],[@CR3]^.

HCC is a complex and multifactorial process. Environmental factors such as exposure to aflatoxin, excess intake of alcohol, liver cirrhosis, and infections with the hepatitis B virus (HBV) or hepatitis C virus (HCV) have been associated with its development. Chronic infections with either the hepatitis B virus (HBV) or the hepatitis C virus (HCV) account for 75% to 80% of HCC cases^[@CR4]^. Deficiencies in the immune response to viral infection are likely an important oncogenic factor in chronic viral carriers. If the T-cell response is not strong enough to completely eliminate the viruses from the liver, chronic liver inflammation may be induced. Inflammation has been suggested to be involved in tumorigenesis via promoting angiogenesis, tumor growth, and DNA damage^[@CR5]--[@CR7]^.

Tumor necrosis factor alpha (TNF-α), a multifunctional cytokine, has a great influence on host immune response to HBV/HCV infection and the pathogenesis of autoimmune and malignant diseases^[@CR8],[@CR9]^. Specifically, it has been implicated in the pathophysiology of liver cancer^[@CR10]^. TNF-α mediates its diverse biologic effects through binding to its two cognate cell surface receptors: tumor necrosis factor receptor superfamily 1A (TNFR1A/TNFR1) and tumor necrosis factor receptor superfamily 1B (TNFR1B/TNFR2), both of which are involved in the regulation of several inflammatory pathways through the activation of transcription factor NF-κB. TNFR1, which has a Fas-like "death domain", is capable of mediating TNF-induced cytotoxicity and TNF-induced cell death. In contrast, the activation of TNFR2 has been shown to be proliferative in hematopoietic cells, particularly T-cells, and it is also known to evoke apoptosis in CD8 cells. In addition, TNFR2 plays a regulatory role in TNF-α's binding to TNFR1^[@CR11]^. In general, most of the nucleated cells are capable of producing TNFR1, whereas TNFR2 expression is restricted primarily to cells of hematopoietic lineage. Increased serum levels of the TNF-TNFR superfamily have been reported in patients with solid tumors and liver disease. The expression of the TNF-TNFR superfamily may influence the development and prognosis of various human cancers^[@CR12]--[@CR14]^. For example, significantly different expression profiles on the part of TNFR2 have been found in 5-FU-non-responding and -responding liver cancer patients^[@CR15]^. Moreover, serum concentrations of TNFRs are significantly associated with increased severity in patients with alcoholic liver disease and with mortality in acute alcoholic hepatitis patients^[@CR15]--[@CR17]^.

The TNFR2 gene, which was mapped on chromosome 1p36.2, has a polymorphism in exon 6 at codon196 (rs1061622, ATG → AGG). There, a T → G substitution results in a non-conservative amino acid change \[methionine (M) → arginine(R)\]. This SNP situated at one of four cysteine-rich domains of TNFR2, a site important for optimal TNF binding, has been reported to affect signal transduction and mRNA stability. Signal transduction by the polymorphic allele (196R) may be more efficient than that by the wild-type allele (196 M). Rs1061624, located in the 3′-untranslated region (UTR) of TNFR2 gene, may have functional consequences through its role in signal transduction or mRNA stability^[@CR18]^.

In addition, TNFR2 gene polymorphism has been associated with a susceptibility to and the progression of various cancers. Such observations have increased our interest in examining the impact of the TNFR2 196 M/R genotype on liver carcinogenesis. To the best of our knowledge, no studies have investigated the association between genetic polymorphisms in TNFR2 and HCC. In the present study, TNFR2 polymorphisms at rs1061622G/T and rs1061624A/G were considered as candidates for investigation in 742 Chinese people. Meanwhile, differences in genotype frequency between the chronic hepatitis (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) cases and healthy controls were examined.

Results {#Sec2}
=======

Characteristics of the study populations {#Sec3}
----------------------------------------

The demographic features of the cases and controls enrolled in this study are represented in Table [1](#Tab1){ref-type="table"}. As compared with the control group, the three case groups (CHB, LC, and HCC) have statistically different laboratory results for sex, age, and ethnicity (P \< 0.05), the CHB group had a higher proportion of alcohol drinkers, and the LC group had a higher proportion of smokers. There were no significant differences in BMI.Table 1Demographic and clinical characteristics of the study subjects.VariablesControlsCHBLCHCCn = 269n = 115P valuen = 86P valuen = 272P valueAge (years) mean ± SD46.62 ± 7.0438.55 ± 12.000.00050.36 ± 12.240.00049.24 ± 11.300.001BMI22.43 ± 3.4122.25 ± 3.540.46722.64 ± 4.070.64222.88 ± 13.080.256Gender, N (%)  Male150 (55.8)89 (77.4)0.00066 (76.7)0.001249 (91.2)0.000  Female119 (44.2)26 (22.6)20 (23.3)24 (8.8)Smoking, N (%)  Yes88 (32.7)49 (42.6)0.06441 (47.7)0.01289 (32.7)0.999  No181 (67.3)66 (57.4)45 (52.3)183 (67.3)Alcohol consumption, N (%)  Yes78 (29.0)57 (49.6)0.00030 (34.9)0.30288 (32.4)0.427  No191 (71.0)58 (50.4)56 (65.1)184 (67.6)Ethnicity, N (%)  Zhuang137 (50.9)44 (38.3)0.04432 (37.2)0.037110 (40.4)0.000  Han117 (43.5)66 (57.4)51 (59.3)155 (57.0)  Others15 (5.6)5 (4.3)3 (3.5)2 (2.6)CHB = chronic hepatitis B, LC = liver cirrhosis, HCC = hepatocellular carcinoma, BMI = body mass index, SD = standard deviation.

Risk assessment between TNFR2 genotypes and CHB {#Sec4}
-----------------------------------------------

The genotype frequency of TNFR2 gene rs1061622 and rs1061624 polymorphisms is listed in Table [2](#Tab2){ref-type="table"}. In the control group, the genotype distributions of rs1061624 were not consistent with the Hardy-Weinberg assumption. We then performed a logistic regression analysis (adjusting for gender, age, ethnicity, smoking, alcohol consumption, and BMI) and found that there was a significant association between TNFR2 rs1061624 polymorphism and CHB susceptibility in the additive model (AA vs. GG) and the recessive model (AA vs. GA+GG), with adjusted ORs of 2.666 (95% CI = 1.126−6.316, P = 0.026) and 2.459 (95% CI = 1.145−5.281, *P* = 0.021), respectively. However, the *TNFR2* rs1061622 polymorphism did not influence susceptibility to CHB in any of the genetic models (additive genetic models: GG vs. TT and TG vs. TT, recessive genetic model: GG vs. TG+TT, and dominant genetic model: GG+TG vs. TT).Table 2Genotype Distributions and Allele Frequencies of TNFR2 Polymorphisms Between Cases and Controls.ModelControlsCHBLCHCCCHB vs ControlsLC vs ControlsHCC vs Controlsn = 269 (%)n = 115 (%)n = 86 (%)n = 272 (%)R(95%CI)\*P\*R(95%CI)\*P\*R(95%CI)\*P\*rs1061622   T460 (85.5)203 (88.3)151 (87.8)469 (86.2)ReferenceReferenceReference   G78 (14.5)27(11.7)21 (12.2)75 (13.8)0.775 (0.453--1.325)0.3520.893 (0.522--1.529)0.6800.964 (0.661--1.407)0.850   TT196 (72.9)90 (78.3)66 (76.7)200 (73.5)ReferenceReferenceReference   TG68 (25.3)23 (20.0)19 (22.1)69 (25.4)0.721 (0.388--1.307)0.2730.884 (0.480--1.628)0.6920.970 (0.631--1.492)0.890   GG5 (1.9)2 (1.7)1 (1.2)3 (1.1)1.001 (0.118--8.519)0.9990.851 (0.090--7.368)0.8550.870 (0.176--4.289)0.864Dominant model   TT196 (72.9)90 (78.3)66 (76.7)200 (73.5)ReferenceReferenceReference   TG + GG73 (27.2)25 (21.7)20 (23.3)72 (26.5)0.725 (0.400--1.314)0.2890.880 (0.483--1.601)0.6750.965 (0.632--1.471)0.867Recessive model   TT + TG264 (98.1)113 (98.3)85 (98.8)269 (98.9)ReferenceReferenceReference   GG5 (1.9)2 (1.7)1 (1.2)3 (1.1)1.104 (0.131--9306)0.9280.845 (0.094--7.593)0.8800.877 (0.178--4.307)0.871rs1061624   G324 (60.2)120 (52.6)87 (51.2)304 (55.7)ReferenceReferenceReference   A214 (39.8)108 (47.4)83 (48.8)242 (44.3)1.363 (0.949--1.959)0.0941.432 (0.995--2.060)0.0531.272 (0.973--1.662)0.078   GG76 (28.3)27 (23.7)14 (16.5)60 (22.0)ReferenceReferenceReference   GA172 (63.9)66 (57.9)59 (69.4)184 (67.4)1.128 (0.625--2.038)0.6891.895 (0.972--3.693)0.061.563 (1.009--2.422)0.046^\#^   AA21 (7.8)21 (18.4)12 (14.1)29 (10.6)2.666 (1.126--6.316)0.026^\#^2.947 (1.130--7.689)0.027^\#^1.955 (0.939--4.073)0.073Dominant model   GG76 (28.3)27 (23.7)14 (16.5)60 (22.0)ReferenceReferenceReference   GA + AA193 (71.7)87 (76.3)72 (83.5)212 (78)1.314 (0.742--2.329)0.3492.016 (1.046--3.887)0.036^\#^1.605 (1.043--2.470)0.031^\#^Recessive model   GG + GA248 (92.8)94 (81.6)74 (85.9)243 (89.4)ReferenceReferenceReference   AA21 (7.8)21 (18.4)12 (14.1)29 (10.6)2.459 (1.145--5.281)0.021^\#^1.830 (0.817--4.099)0.1421.411 (0.703--2.728)0.305\*Adjusted for age, gender, ethnicity, smoking, alcohol consumption,and BMI.^\#^The data reach statistical significance.

Risk assessment between TNFR2 genotypes and LC {#Sec5}
----------------------------------------------

After adjusting for the demographic and clinical factors, variants of TNFR2 rs1061624 were found to be associated with LC development. Patients with the AA genotype and at least one copy of the A allele (dominant model) were found to be at more than double the normal risk of LC (ORs = 2.947 and 2.016, respectively; P \< 0.05). In contrast, the variants of TNFR2 rs1061622 were not found to be associated with LC risk.

Risk estimation between TNFR2 genotypes and HCC {#Sec6}
-----------------------------------------------

In our binary logistic regression analyses, the data showed that individuals with the TNFR2 rs1061624 GA genotype had an approximately 50% increased risk of HCC (OR = 1.563, 95% CI = 1.009−2.422, *P* = 0.046) after adjusting for age, gender, smoking, alcohol consumption, and BMI. Furthermore, the data in the dominant model (GA+AA vs. GG) also showed a significantly increased risk of HCC among such individuals (OR = 1.605, 95% CI = 1.043−2.470, P = 0.031). However, the present data revealed that the TNFR2 rs1061622 polymorphism was not associated with HCC risk.

Risk estimation between TNFR2 genotypes and HBV-related diseases according to gender {#Sec7}
------------------------------------------------------------------------------------

The gender-stratification of TNFR2 polymorphisms indicated that their implications were mostly restricted to male subjects (Table [3](#Tab3){ref-type="table"}). For rs1061624, significantly increased CHB risk was found among male subjects in the allele model A vs. G (OR = 1.668, 95% CI = 1.056--2.634, *P* = 0.022), the additive model AA vs. GG (OR = 4.280, 95% CI = 1.405--13.041, P = 0.026), and the recessive model AA vs. AG+GG (OR = 3.032, 95% CI = 1.146−8.021, P = 0.025). A significantly increased LC risk was found among male subjects in the additive model AA vs. GG (OR = 3.361, 95% CI = 1.114−10.146, *P* = 0.031). In contrast, the present data indicate no differences in the genotype distributions of TNFR2 rs1061622 among male and female subjects (data not shown).Table 3Risk estimation between TNFR2 genotypes and HBV-related diseases in males.SNPCHB vs ControlsLC vs ControlsHCC vs ControlsR(95%CI)\*P\*R(95%CI)\*P\*R(95%CI)\*P\*rs1061622   TReferenceReferenceReference   G0.718 (0.362--1.421)0.3410.778 (0.392--1.545)0.4741.043 (0.684--1.591)0.845   TTReferenceReferenceReference   TG0.698 (0.327--1.488)0.3510.656 (0.301--1.430)0.2891.108 (0.687--1.787)0.647   GG0.374 (0.007--20.029)0.6291.878 (0.154--22.876)0.6210.625 (0.085--4.585)0.644Dominant model   TTReferenceReferenceReference   TG + GG0.688 (0.342--1.461)0.3310.695 (0.325--1.483)0.2461.082 (0.677--1.731)0.742Recessive model   TT+TGReferenceReferenceReference   GG0.431 (0.008--23.782)0.6812.129 (0.352--1.483)0.3460.610 (0.084--4.452)0.626rs1061624   GReferenceReferenceReference   A1.668 (1.056--2.634)0.028^\#^1.492 (0.972--2.288)0.0671.268 (0.943--1.705)0.116   GGReferenceReferenceReference   GA1.649 (0.767--3.547)0.2001.747 (0.824--3.703)0.1461.548 (0.966--2.479)0.069   AA4.280 (1.405--13.041)0.011^\#^3.361 (1.114--10.146)0.031^\#^1.882 (0.831--4.267)0.130Dominant model   GGReferenceReferenceReference   GA + AA1.953 (0.928--4.108)0.0780.519 (0.249--1.084)0.0811.584 (0.997--2.517)0.052Recessive model   GG+GAReferenceReferenceReference   AA3.032 (1.146--8.021)0.025^\#^2.258 (0.867--5.878)0.0951.381 (0.653--2.920)0.398\*Adjusted for age, gender,ethnicity, smoking and alcohol consumption, and BMI.^\#^The data reaches a statistical significant level.

Discussion {#Sec8}
==========

HBV is a prototype member of the Hepadnaviridae family of viruses. These viruses can induce chronic and persistent infections accompanied by immune-mediated liver injury in the infected host. Persistent HBV infection is a major risk factor for the development of hepatic decompensation, cirrhosis, and in particular, hepatocellular carcinoma^[@CR19]^. Hepatitis B is among the most important infectious diseases in China. More than 120 million people are reportedly to be HBV carriers. An estimated 20 million suffer from CHB, and almost 300,000 die annually from the chronic consequences of HBV infection, such as HBV-related LC or HCC^[@CR20]^. To our knowledge, this is the first study to investigate the association between SNPs of TNFR2 and the presence of CHB, HBV-related LC, and HBV-related HCC in a Chinese population. We demonstrate, for the first time, that rs1061624 in TNFR2 is strongly associated with an increased risk of CHB, LC, and HCC. Nevertheless, such an effect was not observed for rs1061622.

The pathogenesis of HBV is complex. HBV itself is not directly cytotoxic, and most of the liver injury is mediated by the host immune response^[@CR9]^. TNF-α plays a major role in the pathogenesis of HBV-induced liver injury. It can compromise immune-mediated virological control and further cause collateral hepatocyte damage and cirrhosis and potentially promote hepatocellular carcinoma. Several studies have described high levels of TNF-α in patients with HBV infection^[@CR9]^. The pleiotropic effects were created via the TNFR1 and TNFR2 hepatocyte membrane receptors. TNFR2, identified as a survival factor for the immune cell subset, has been reported in the context of inflammation. Lacking or overexpressing TNFR-2 results in a severe inflammatory syndrome^[@CR21],[@CR22]^. TNFR2 signaling has been found to have an effect on anti-viral and anti-tumor activity in hepatocytes and myeloid cells. Ping *et al*.^[@CR23]^ reported that TNFR2 is associated with heart failure risk in type 2 diabetes mellitus patients. Ham *et al*.^[@CR12]^ found that TNFR2 plays distinct roles in the response of the hepatic microenvironment to tumor cell entry into the liver, with TNFR2 knockout being detrimental to the growth of liver metastases. According to Heemann *et al*.^[@CR13]^, elevations of circulating levels of TNFR and high circulating levels of soluble TNFR2 are negative predictors of treatment response in T-cell non-Hodgkin lymphomas.

Given that TNFR2 plays an important role in inflammation and carcinogenesis, SNPs in TNFR2 may affect cell phenotypes and cause the risk of developing inflammation-related diseases. SNPs in TNFR2 have been associated with susceptibility to Human T-cell lymphotropic virus type I, which is associated myelopathy breast cancer^[@CR24]^ and systemic lupus erythematosus^[@CR25]^, and SNPs in TNFE2 have been also associated with survival in breast cancer^[@CR26]^ and non-small cell lung cancer cases^[@CR27]^. Only one study to date has examined the association between TNFR2 polymorphisms and the risk of liver disease. Nguyen *et al*.^[@CR28]^ investigated the influence of TNFR2 T676G polymorphisms on severe acute alcoholic hepatitis. The findings of these researchers did not support an association.

HBV-related diseases are more common in males than females. In the present study, we observed a gender difference regarding the degree to which the TNFR2 rs1061624 polymorphism affects CHB and LC risk. Males who carried the rs1061624 AA genotype were at a significantly higher risk of CHB and LC. In contrast, these differences were not observed in females. The mechanisms underlying this gender difference remain unknown. The potentially elevated risk in males may be due to the small number of patients examined in our series. On the other hand, males' increased exposure to toxic effects (such as tobacco and alcohol abuse) may account for the problem.

In summary, the data presented in this study show, for the first time, that rs1061624 polymorphism in TNFR2 is associated with CHB, LC,and HCC in Chinese patient population with HBV, particularly for males. Detection of this polymorphism could serve as a potential marker in prediction of risk of development of HBV-related diseases. However, these observations were based on a genetic analysis of a single gene using a relatively small sample of patients with HBV-related diseases. Thus, the results should be further validated using an independent prospective clinical study.

Materials and Methods {#Sec9}
=====================

Study population {#Sec10}
----------------

Among the patients with chronic hepatitis B virus infection who were admitted to the First Affiliated Hospital of Guangxi Medical University from April 2014 to October 2014, 473 patients were selected. One hundred and fifteen had CHB, 86 had HBV-induced liver cirrhosis (LC) and 272 had HCC. All of the patients were positive for HBsAg, anti-HBc, and hepatitis B e antigen (HBeAg) or hepatitis B e antibody (HBeAb) for at least 6 months. The diagnoses of individuals were based on a thorough history, clinical examination, and laboratory evaluation.

CHB was defined as (i) being HBsAg-positive for at least six months and (ii) having serum levels of ALT or AST is greater than 40 IU/mL. LC was defined based on (i) clinical symptoms and characteristic, (ii) pathologic exams or typical morphologic findings upon computed tomography (CT) or ultrasonography, and (iii) laboratory features. HBV-HCC subjects were confirmed using histological or cytological methods or AFP levels higher than 400 ng/mL that were associated with at least one positive imaging result, such as computed tomography (CT), magnetic resonance imaging (MRI) or ultrasonography. During the same study period, 269 unrelated healthy controls who visited the general health check-up centers at the same hospitals were also enrolled. The inclusion criterion for the controls was the absence of any evidence of a prior history of cancer or any other serious illness.

Demographic data from each individual, such as gender, age, body mass index (BMI), ethnicity, smoking status, and alcohol consumption status were collected. All individuals were Chinese and were from Guangxi district. Informed consent was obtained from each individual regarding the use of their DNA. The ethics committee of the First Affiliated Hospital of Guangxi Medical University approved the study protocol. Additionally, all of the methods in this study were carried out in accordance with the principles of the Declaration of Helsinki.

DNA extraction {#Sec11}
--------------

Genomic DNA was extracted from peripheral blood mono-nuclear cells (sampled in an EDTA tube) using the QIAamp DNA blood mini kit as described by the manufacturer (Qiagen, Hilden, Germany) and stored at −80 °C until use.

Genotype analysis {#Sec12}
-----------------

TNFR2 gene polymorphisms (rs1061622G/T and rs1061624A/G) were examined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The primer sequences, the restriction enzymes used, and the length of the resulting polymerase chain reaction products are given in Table [4](#Tab4){ref-type="table"}. In addition, to validate the results of the genotyping assays, 10% of the PCR-amplified DNA samples were randomly selected and examined via DNA sequencing in an ABI PRISM 3730 (Figs [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). The results were 100% concordant.Table 4Primer Sequence and the Reaction Condition for Genotyping TNFR2 Polymorphisms.SNPPrimer SequenceAnnealing temperatureProduct size (bp)Restriction enzymers1061622Forward:5′-TCCTCCAGCTGTAACGTGG-3′63 °CTT:246 bp, 45 bpHin1IIReverse:5′-GACAGGCAGACAGAAGGAGT-3′GG:291 bpTG:291 bp, 246 bp, 45 bprs1061624Forward:5′-TGGGCCAAGTTCCTCTAGTG-3′58 °CGG:71 bp, 106 bpMspA1IReverse:5′-CAGGTCACAGAGAGTCAGGG-3′AA:177 bpGA:177 bp, 71 bp, 106 bpFigure 1Sequencing map of the genotype for the TNFR2 rs1061622 polymorphism. Arrow in parts (**a**--**c**) indicates GG, G/T and TT genotypes, respectively.Figure 2Sequencing map of the genotype for the TNFR2 rs1061624 polymorphism. Arrow in parts (**a**--**c**) indicates GG, G/A, and AA genotypes, respectively.

Statistical analysis {#Sec13}
--------------------

Statistical analyses were conducted using SPSS 16.0 software. The demographic and clinical data were compared between groups via a one-way ANOVA test for continuous variables and a chi-squared test or Fisher's exact test (when the expected number in any cell was less than five) for categorical variables. The odds ratio (OR) with its corresponding 95% confidence interval (95% CI) were used to assess the strength of each association. Logistic regression analysis was used to adjust the statistical findings for age, gender, BMI, ethnicity, smoking status, and alcohol consumption status. The probability of Hardy-Weinberg equilibrium (HWE) in each group was tested using the chi-squared test. All statistical tests listed above were two tailed, and p \< 0.05 was considered statistically significant.

Data availability {#Sec14}
-----------------
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